Cybin Corp.

NEO: CYBN

Company Logo

Company Overview

Cybin is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Financial Highlights

$0

Revenue (ttm)

-$311,000

Gross Profit (ttm)

-$0.34

Diluted EPS (ttm)

Management Team

Mr. Eric So L.L.B., LLB
Co-Founder, Pres & Exec. Chairman

Mr. Douglas L. Drysdale
Chief Exec. Officer

Mr. Paul Glavine
Co-Founder, Chief Growth Officer & Director

Mr. John Kanakis
Co-Founder & Chief Bus. Officer

Mr. Greg Cavers
Chief Financial Officer

Mr. Aaron Bartlone
Chief Operating Officer

Dr. Alex L. Nivorozhkin Ph.D.
Chief Scientific Officer

Mr. Gabriel Fahel
Chief Legal Officer

Sara Brittany Somerset
Chief Communications Officers

Lori Challenger
Chief of Staff

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
0 (0%)

Insider Ownership
16%